J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will ...

Carotuximab plus Erleada proved safe in the first 10 patients with metastatic castration-resistant prostate cancer dosed on ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Johnson & Johnson has announced the submission of an extension of indication application to the European Medicines Agency (EMA) seeking approval of Akeega (niraparib/abiraterone acetate) with ...

The addition of metformin “was generally well tolerated but did not result in the targeted benefit of a 20% reduction in risk of death in an unselected population,” the researchers wrote.

The report provides a detailed analysis of the current marketed drugs and late-stage pipeline drugs.

Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored ...

Johnson & Johnson (NYSE:JNJ) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On July 3, Janssen-Cilag, a ...